Skip to main content
Equibles

BARCLAYS PLC

Position in FTRE — Fortrea Holdings Inc.

CIK 312069 LONDON, X0
Back to FTRE Full portfolio

Position in FTRE

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$3,438,883
+$1,604,575 QoQ
Shares Held
197,637
+1.5% QoQ
Ownership
0.208%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#59
of 334 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in FTRE Over Time

Shares Held

Position Value (USD)

Derivatives in FTRE

reported options exposure · as of Dec 31, 2024
CallValue
$1,215,980
CallShares
65,200
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

BARCLAYS PLC holds $1,710,275,600 across 455 Biotechnology names. FTRE ranks #49 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 733,274 $364,239,192
2 REGN
Regeneron Pharmaceuticals, Inc.
 256,192 $159,745,957
3 IONS
Ionis Pharmaceuticals Inc
 1,603,136 $127,112,653
4 ARGX
Argenx SE
 134,427 $124,717,337
5 MRNA
Moderna, Inc.
 1,035,126 $72,489,872
6 BBIO
BridgeBio Pharma, Inc.
 714,423 $53,210,224
7 TGTX
Tg Therapeutics, Inc.
 957,848 $52,624,168
8 DNTH
Dianthus Therapeutics, Inc. /DE/
 431,753 $42,087,281

All Filings in FTRE

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,438,883 197,637
2026-03-31 $1,834,308 194,725
2025-12-31 $5,976,141 346,443
2025-09-30 $2,959,039 351,430
2025-06-30 $2,409,004 487,653
2025-03-31 $2,406,026 318,679
2024-12-31 $1,215,980 65,200
2024-12-31 $8,687,673 465,827
2024-09-30 $7,850,080 392,504
2024-09-30 $1,304,000 65,200
2024-06-30 $1,400,400 60,000
2024-06-30 $1,268,528 54,350
2024-03-31 $2,620,940 65,295
2023-12-31 $771,464 22,105
2023-09-30 $16,391,646 573,335